XML 37 R62.htm IDEA: XBRL DOCUMENT
v2.4.1.9

LICENSE AGREEMENTS (Details) (USD $) | 0 Months Ended | 12 Months Ended
--- | --- | ---
Dec. 15, 2014 item | Dec. 31, 2014
LICENSE AGREEMENTS |  |
Amount expected to be recognized as revenue |  | $ 35,000,000us-gaap_DeferredRevenue
Expected Revenue |  |
LICENSE AGREEMENTS |  |
Amount expected to be recognized as revenue |  | 35,000,000us-gaap_DeferredRevenue / us-gaap_StatementScenarioAxis = gern_CollaborativeArrangementExpectedRevenueMember
License agreements | Janssen Biotech | Initial Period |  |
LICENSE AGREEMENTS |  |
Upfront payment received |  | 35,000,000gern_UpfrontPaymentReceivedFromJanssenUnderCollaborationAgreement / us-gaap_CounterpartyNameAxis = us-gaap_CollaborativeArrangementMember / us-gaap_StatementScenarioAxis = gern_InitialPeriodMember / us-gaap_TypeOfArrangementAxis = gern_JanssenBiotechIncMember
Number of agreed upon studies | 2gern_CollaborativeArrangementNumberOfStudies / us-gaap_CounterpartyNameAxis = us-gaap_CollaborativeArrangementMember / us-gaap_StatementScenarioAxis = gern_InitialPeriodMember / us-gaap_TypeOfArrangementAxis = gern_JanssenBiotechIncMember |
Percentage of costs to be paid by Geron |  | 50.00%gern_CollaborativeArrangementGeronCostSharingPercentage / us-gaap_CounterpartyNameAxis = us-gaap_CollaborativeArrangementMember / us-gaap_StatementScenarioAxis = gern_InitialPeriodMember / us-gaap_TypeOfArrangementAxis = gern_JanssenBiotechIncMember
Percentage of costs to be paid by Janssen |  | 50.00%gern_CollaborativeArrangementJanssenCostSharingPercentage / us-gaap_CounterpartyNameAxis = us-gaap_CollaborativeArrangementMember / us-gaap_StatementScenarioAxis = gern_InitialPeriodMember / us-gaap_TypeOfArrangementAxis = gern_JanssenBiotechIncMember
Notification period |  | 24 months
License agreements | Janssen Biotech | U.S. Opt-In Rights exercised |  |
LICENSE AGREEMENTS |  |
Percentage of costs to be paid by Geron |  | 20.00%gern_CollaborativeArrangementGeronCostSharingPercentage / us-gaap_CounterpartyNameAxis = us-gaap_CollaborativeArrangementMember / us-gaap_StatementScenarioAxis = gern_RightsExercisedMember / us-gaap_TypeOfArrangementAxis = gern_JanssenBiotechIncMember
Percentage of costs to be paid by Janssen |  | 80.00%gern_CollaborativeArrangementJanssenCostSharingPercentage / us-gaap_CounterpartyNameAxis = us-gaap_CollaborativeArrangementMember / us-gaap_StatementScenarioAxis = gern_RightsExercisedMember / us-gaap_TypeOfArrangementAxis = gern_JanssenBiotechIncMember
Continuation Election milestone payment |  | 65,000,000gern_CollaborativeArrangementContinuationElectionMilestonePayment / us-gaap_CounterpartyNameAxis = us-gaap_CollaborativeArrangementMember / us-gaap_StatementScenarioAxis = gern_RightsExercisedMember / us-gaap_TypeOfArrangementAxis = gern_JanssenBiotechIncMember
Aggregate maximum total payments for development and regulatory milestones under collaboration agreement |  | 470,000,000gern_CollaborativeArrangementDevelopmentAndRegulatoryMilestonesAggregateMaximum / us-gaap_CounterpartyNameAxis = us-gaap_CollaborativeArrangementMember / us-gaap_StatementScenarioAxis = gern_RightsExercisedMember / us-gaap_TypeOfArrangementAxis = gern_JanssenBiotechIncMember
Aggregate maximum total of payments for sales milestones under collaboration agreement |  | 350,000,000gern_CollaborativeArrangementSalesMilestonesAggregateMaximum / us-gaap_CounterpartyNameAxis = us-gaap_CollaborativeArrangementMember / us-gaap_StatementScenarioAxis = gern_RightsExercisedMember / us-gaap_TypeOfArrangementAxis = gern_JanssenBiotechIncMember
Tiered royalties percentage, low end of the range |  | mid-teens
Tiered royalties percentage, high end of the range |  | low twenties
U.S. selling effort percentage |  | 20.00%gern_CollaborativeArrangementSellingEffortPercentage / us-gaap_CounterpartyNameAxis = us-gaap_CollaborativeArrangementMember / us-gaap_StatementScenarioAxis = gern_RightsExercisedMember / us-gaap_TypeOfArrangementAxis = gern_JanssenBiotechIncMember
License agreements | Janssen Biotech | U.S. Opt-In Rights not exercised |  |
LICENSE AGREEMENTS |  |
Continuation Election milestone payment |  | 65,000,000gern_CollaborativeArrangementContinuationElectionMilestonePayment / us-gaap_CounterpartyNameAxis = us-gaap_CollaborativeArrangementMember / us-gaap_StatementScenarioAxis = gern_RightsNotExercisedMember / us-gaap_TypeOfArrangementAxis = gern_JanssenBiotechIncMember
Full U.S. Rights fee |  | 70,000,000gern_CollaborativeArrangementFullUSRightsFee / us-gaap_CounterpartyNameAxis = us-gaap_CollaborativeArrangementMember / us-gaap_StatementScenarioAxis = gern_RightsNotExercisedMember / us-gaap_TypeOfArrangementAxis = gern_JanssenBiotechIncMember
Aggregate maximum total payments for development and regulatory milestones under collaboration agreement |  | 415,000,000gern_CollaborativeArrangementDevelopmentAndRegulatoryMilestonesAggregateMaximum / us-gaap_CounterpartyNameAxis = us-gaap_CollaborativeArrangementMember / us-gaap_StatementScenarioAxis = gern_RightsNotExercisedMember / us-gaap_TypeOfArrangementAxis = gern_JanssenBiotechIncMember
Aggregate maximum total of payments for sales milestones under collaboration agreement |  | $ 350,000,000gern_CollaborativeArrangementSalesMilestonesAggregateMaximum / us-gaap_CounterpartyNameAxis = us-gaap_CollaborativeArrangementMember / us-gaap_StatementScenarioAxis = gern_RightsNotExercisedMember / us-gaap_TypeOfArrangementAxis = gern_JanssenBiotechIncMember
Tiered royalties percentage, low end of the range |  | double-digit
Tiered royalties percentage, high end of the range |  | mid-teens
License agreements | Janssen Biotech | Collaborative Arrangement Development IP Jointly Or Solely Owned |  |
LICENSE AGREEMENTS |  |
Percentage of costs to be paid by Geron |  | 50.00%gern_CollaborativeArrangementGeronCostSharingPercentage / us-gaap_CounterpartyNameAxis = us-gaap_CollaborativeArrangementMember / us-gaap_StatementScenarioAxis = gern_CollaborativeArrangementDevelopmentIpJointlyOrSolelyOwnedMember / us-gaap_TypeOfArrangementAxis = gern_JanssenBiotechIncMember
Percentage of costs to be paid by Janssen |  | 50.00%gern_CollaborativeArrangementJanssenCostSharingPercentage / us-gaap_CounterpartyNameAxis = us-gaap_CollaborativeArrangementMember / us-gaap_StatementScenarioAxis = gern_CollaborativeArrangementDevelopmentIpJointlyOrSolelyOwnedMember / us-gaap_TypeOfArrangementAxis = gern_JanssenBiotechIncMember

X
- Definition The amount of consideration that Geron could receive upon Janssen providing a positive Continuation Election notice. + References No definition available. + Details
Name: | gern_CollaborativeArrangementContinuationElectionMilestonePayment
Namespace Prefix: | gern_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents the aggregate maximum consideration that Geron could receive from attaining certain development and regulatory milestone events under the collaboration agreement. + References No definition available. + Details
Name: | gern_CollaborativeArrangementDevelopmentAndRegulatoryMilestonesAggregateMaximum
Namespace Prefix: | gern_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents the consideration that Geron will receive from Janssen upon Geron's decision to opt-out of further development cost sharing after Janssen's positive Continuation Election notice. + References No definition available. + Details
Name: | gern_CollaborativeArrangementFullUSRightsFee
Namespace Prefix: | gern_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents the percentage of costs that Geron must pay during certain phases of the agreement. + References No definition available. + Details
Name: | gern_CollaborativeArrangementGeronCostSharingPercentage
Namespace Prefix: | gern_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the percentage of costs that Janssen must pay during certain phases of the agreement. + References No definition available. + Details
Name: | gern_CollaborativeArrangementJanssenCostSharingPercentage
Namespace Prefix: | gern_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the latest notification period from Janssen to Geron in the event of early termination or suspension of the Initial Phase 2 MF Study. + References No definition available. + Details
Name: | gern_CollaborativeArrangementNotificationPeriod
Namespace Prefix: | gern_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the number of agreed upon studies. + References No definition available. + Details
Name: | gern_CollaborativeArrangementNumberOfStudies
Namespace Prefix: | gern_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the aggregate maximum consideration that Geron could receive from attaining certain sales milestone events under the collaboration agreement. + References No definition available. + Details
Name: | gern_CollaborativeArrangementSalesMilestonesAggregateMaximum
Namespace Prefix: | gern_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents the percentage of sales effort that Geron can provide in lieu of funding the same percentage of promotion costs upon regulatory approval and commercial launch of imetelstat in the U.S. + References No definition available. + Details
Name: | gern_CollaborativeArrangementSellingEffortPercentage
Namespace Prefix: | gern_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the high end of the range of tiered royalty percentages to be applied to worldwide net sales of imetelstat. + References No definition available. + Details
Name: | gern_CollaborativeArrangementTieredRoyaltiesPercentageHighEndOfRange
Namespace Prefix: | gern_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the low end of the range of tiered royalty percentages to be applied to worldwide net sales of imetelstat. + References No definition available. + Details
Name: | gern_CollaborativeArrangementTieredRoyaltiesPercentageLowEndOfRange
Namespace Prefix: | gern_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Upfront payment received from Janssen upon effectiveness of Collaboration Agreement. + References No definition available. + Details
Name: | gern_UpfrontPaymentReceivedFromJanssenUnderCollaborationAgreement
Namespace Prefix: | gern_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 13 -Section A Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 13.A.4(a).Q1 Response) -URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780 + Details
Name: | us-gaap_DeferredRevenue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Details
Name: | us-gaap_CounterpartyNameAxis=us-gaap_CollaborativeArrangementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementScenarioAxis=gern_CollaborativeArrangementExpectedRevenueMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |